Efficacy of hydrolytic enzymes in preventing radiation therapy-induced side effects in patients with head and neck cancers

Cancer Chemotherapy and Pharmacology, Supplement

Volumn 47, Issue 7, 2001, Pages S23-S28

  Gujral, Malook S ^a   Patnaik, Pravas M ^b   Kaul, Rashmi ^a   Parikh, Hemen K ^c   Conradt, Christian ^d   Tamhankar, Chetan P ^e   Daftary, Gautam V ^e,f  

^a SGPT Cancer Hospital   (India)

^b Acharya Harihar Regional Cancer Centre for Cancer Research & Treatment Society Cuttack   (India)

^c TATA MEMORIAL HOSPITAL   (India)

^d UNIVERSITY OF HEIDELBERG   (Germany)

^e SIRO Research Foundation   (India)

^f SIRO Research Foundation   (India)

Author keywords

Acute reaction; Enzyme therapy; Mucositis; Radiation therapy; Side effects; Supportive care

Indexed keywords

CHYMOTRYPSIN; COBALT 60; PAPAIN; PROTEINASE; TRYPSIN; WOBENZYM;

ADULT; CANCER RADIOTHERAPY; CANCER STAGING; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; COBALT THERAPY; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFECT; DRUG EFFICACY; DRUG TOLERABILITY; DYSPHAGIA; EDEMA; FEMALE; FEVER; GAMMA RADIATION; HEAD AND NECK CANCER; HEMOPTYSIS; HUMAN; INDIA; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; MULTICENTER STUDY; PAIN; PRIORITY JOURNAL; RADIATION DOSE; RADIATION INJURY; RADIATION PROTECTION; RANDOMIZED CONTROLLED TRIAL; SKIN MANIFESTATION;

ACUTE DISEASE; CARCINOMA, SQUAMOUS CELL; CHYMOTRYPSIN; DEGLUTITION DISORDERS; DRUG COMBINATIONS; ENDOPEPTIDASES; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MIDDLE AGED; PAPAIN; PROSPECTIVE STUDIES; RADIATION INJURIES; RADIATION-PROTECTIVE AGENTS; RADIOTHERAPY; SKIN; STOMATITIS; TRYPSIN;

EID: 0034925393     PISSN: 09439404     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Randomized clinical trial on accelerated 7 days per week fractionation in radiotherapy for head and neck cancer. Preliminary report on acute toxicity
2. Primary site as predictive factor of local control in advanced head and neck tumors treated by concomitant boost accelerated radiotherapy
3. Accelerated radiation therapy in the treatment of very advanced and inoperable head and neck cancers
4. The efficacy of sucralfate suspension in the prevention of oral mucositis due to radiation therapy
5. Vitamin E in the treatment of chemotherapy-induced mucositis
6. Treatment complications after sequential combination chemotherapy and radiotherapy with or without surgery in previously untreated squamous cell carcinoma of the head and neck
7. Cancer therapy and oral mucositis. An appraisal of drug prophylaxis
8. Mucosal protectants and their application for head and neck chemoirradiation
9. Efficacy and safety of granulocyte macrophage-colony stimulating factor (GM-CSF) on the frequency and severity of radiation mucositis in patients with head and neck carcinoma
10. Effect of prophylactic sucralfate suspension on stomatitis induced by cancer chemotherapy. A randomized, double-blind cross-over study
11. Topical PGE2 enhances healing of chemotherapy-associated mucosal lesions
12. Ars curandi
13. The effect of orally administered proteolytic enzymes on the postoperative course of periodontal surgery
14. Preventive and corrective treatment of inflammatory edemas in dentistry and maxillofacial surgery, particularly by means of proteolytic enzymes of vegetable origin
15. Evaluation of an oral proteolytic enzyme in operations upon the hand
16. Evaluation of the efficacy of prcteolytic enzymes by oral route in the control of postsurgical inflammation of the hand
17. Clinical effects of proteolytic enzymes after reconstructive hand surgery. A double-blind evaluation of oral trypsin-chymotrypsin
18. Prophylaxis and treatment of postoperative and posttraumatic edema in the jaw and face region
19. Radiotherapy by multiple fractions per day (MFD) in head and neck cancer: Acute reactions of skin and mucosa
20. Sucralfate mouth washing in the prevention of radiation-induced mucositis: A placebo-controlled double-blind randomized study
21. Continuous course radiation therapy and concurrent combination chemotherapy for squamous cell head and neck cancer
22. Immunomodulation by proteolytic enzymes
23. TGF-β1 levels in pre-treatment plasma identify breast cancer patients at risk of developing post-radiotherapy fibrosis